Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of the HIV-1-infected men followed longitudinally before and after initiation of antiretroviral treatment that are shown in Figures 3 and 4

From: HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells

PRE/POST Antiretroviral treatment Number or Median (IQR)
Number of patients 16
Age (years) 36 (24–40)
Antiretroviral treatment regimen  
Non-Nucleoside Reverse Transcriptase Inhibitors 8
Protease Inhibitors 7
Integrase Inhibitors 1
Time from diagnosis to antiretroviral treatment (months) 2 (1.5-5)
Time between samples (months) 11 (7–19)
CD4+ T-cell count (cells/μl)  
PRE antiretroviral treatment 297 (239–316)
POST antiretroviral treatment 505 (401–597)
Plasma Viral Load (Log10 HIV RNA copies/ml)  
PRE antiretroviral treatment 5 (4.4-5.5)
POST antiretroviral treatment 1.7 (1.4-1.7)